CD45-PET is a robust, non-invasive tool for imaging inflammation

Ali Salehi Farid, Jennifer E. Rowley, Harris H. Allen, Isabella G. Kruger, Soheil Tavakolpour, Kyle Neeley, Min Cong, Haneyeh Shahbazian, Niki Dorafshani, Achraf Berrada, Alexander C. MacDonagh, Robert F. Padera, Pedro Brugarolas, Alan B. Packard, Matthew W. Rosenbaum, Sanjay Divakaran, Marcelo F. Carli and Mohammad Rashidian ()
Additional contact information
Ali Salehi Farid: Dana-Farber Cancer Institute
Jennifer E. Rowley: Dana-Farber Cancer Institute
Harris H. Allen: Dana-Farber Cancer Institute
Isabella G. Kruger: Dana-Farber Cancer Institute
Soheil Tavakolpour: Dana-Farber Cancer Institute
Kyle Neeley: Dana-Farber Cancer Institute
Min Cong: Dana-Farber Cancer Institute
Haneyeh Shahbazian: Dana-Farber Cancer Institute
Niki Dorafshani: Dana-Farber Cancer Institute
Achraf Berrada: Dana-Farber Cancer Institute
Alexander C. MacDonagh: Massachusetts General Hospital
Robert F. Padera: Harvard Medical School
Pedro Brugarolas: Harvard Medical School
Alan B. Packard: Harvard Medical School
Matthew W. Rosenbaum: Harvard Medical School
Sanjay Divakaran: Harvard Medical School
Marcelo F. Carli: Harvard Medical School
Mohammad Rashidian: Dana-Farber Cancer Institute

Nature, 2025, vol. 639, issue 8053, 214-224

Abstract: Abstract Imaging inflammation holds immense potential for advancing the diagnosis, treatment and prognosis of many conditions1–3. The lack of a specific and sensitive positron emission tomography (PET) probe to detect inflammation is a critical challenge. To bridge this gap, we present CD45-PET imaging, which detects inflammation with exceptional sensitivity and clarity in several preclinical models. Notably, the intensity of the CD45-PET signal correlates robustly with the severity of disease in models of inflammatory lung and bowel diseases, outperforming 18F-fluorodeoxyglucose PET, the most widely used imaging modality for inflammation globally. Longitudinal CD45-PET imaging further enables precise monitoring of dynamic changes in tissue-specific inflammatory profiles. Finally, we developed a human CD45-PET probe for clinical translation that effectively detects human immune cells in a humanized mouse model. CD45-PET imaging holds substantial clinical promise, offering a tool for guiding diagnostic and therapeutic decisions for inflammatory diseases through a precise, whole-body assessment of the inflammation profiles of individual patients.

Date: 2025
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41586-024-08441-6 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:639:y:2025:i:8053:d:10.1038_s41586-024-08441-6

Ordering information: This journal article can be ordered from
https://www.nature.com/

DOI: 10.1038/s41586-024-08441-6

Access Statistics for this article

Nature is currently edited by Magdalena Skipper

More articles in Nature from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().